10-Q: Nkarta Reports Q1 2026 Financials, Focuses on NKX019 Development

Sentiment:

Quarterly Report 12 May 2026 4:09 PM

Nkarta, Inc. filed its Q1 2026 Form 10-Q, detailing a net loss of $27.8 million and continued investment in its lead CAR NK cell therapy candidate, NKX019, for autoimmune diseases.

Capital raiseThe company states it will need substantial additional funding to support continuing operations and pursue its long-term development strategy.Nkarta intends to raise such capital through debt or equity financings or other arrangements.The company has a Shelf Registration Statement filed and declared effective, covering the offer and sale of up to $350.0 million in aggregate offering price of various securities, including an at-the-market equity offering program of up to $100.0 million.

Worse than expectedThe company reported a net loss of $27.8 million for the quarter, which is a continuation of its historical trend of incurring significant operating losses.While operating expenses decreased, this was primarily due to a reduction in general and administrative costs, including severance expenses from a prior workforce reduction, rather than a decrease in core R&D spending.Research and development expenses increased slightly, indicating continued investment in pipeline development, which contributes to the ongoing net loss.

Summary

Nkarta, Inc. reported a net loss of $27.8 million for the first quarter ended March 31, 2026, compared to a net loss of $31.9 million in the same period of 2025.
Total operating expenses decreased to $30.9 million from $36.6 million in Q1 2025, primarily due to lower general and administrative expenses.
Research and development expenses increased slightly to $25.0 million from $24.2 million, driven by higher clinical spending for NKX019.
The company had cash, cash equivalents, restricted cash, and investments totaling $266.7 million as of March 31, 2026.
Management believes current resources are sufficient to fund operations for at least the next 12 months.
Nkarta is advancing NKX019, a CAR NK cell therapy candidate, for autoimmune diseases, with ongoing Phase 1/2 clinical trials (Ntrust-1 and Ntrust-2).
The company announced agreement with the FDA on protocol amendments for Ntrust-1 and Ntrust-2 to enable outpatient administration and the option to re-dose patients.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the continued net loss and the company's reliance on future capital raises, despite some positive developments in clinical trial protocol amendments.

Positives

Reduction in overall operating expenses by $5.7 million compared to the prior year's quarter.
Successful agreement with the FDA on protocol amendments for NKX019 clinical trials to allow for outpatient administration and re-dosing, potentially improving patient access and trial efficiency.
Sufficient liquidity with $266.7 million in cash, cash equivalents, and investments, expected to cover operations for at least 12 months.
Continued progress in clinical development of NKX019 for autoimmune diseases, with ongoing trials and positive engagement with regulatory bodies.

Negatives

Net loss of $27.8 million for the quarter, indicating continued operational losses.
Decrease in interest income by $1.5 million due to lower investment balances and interest rates.
Deprioritization of earlier pipeline programs (NKX101 and NKX070) and deprioritization of NKX019 for B-cell malignancies, indicating a narrowed focus.
The company has a limited operating history and no products approved for sale, with significant losses incurred since inception.

Risks

The company has a limited operating history and no products approved for sale.
Nkarta has incurred significant losses since inception and expects to continue incurring significant losses for the foreseeable future.
The company will require additional capital, which may cause dilution to stockholders or restrict operations.
The business depends on the success of its CAR NK-cell technology platform, which is novel and faces significant development challenges.
Clinical development is lengthy, expensive, and uncertain, with potential for substantial delays.
The company may fail to develop NKX019 or other product candidates successfully or obtain regulatory approval.
Clinical data supporting CD19-targeted cell therapies for autoimmune diseases are limited, and NKX019's efficacy against B-cell mediated autoimmune diseases is not guaranteed.
Patient enrollment and retention in clinical trials are challenging and time-consuming.
Manufacturing processes are novel and complex, posing risks of production difficulties and supply shortages.
Reliance on third-party suppliers for critical manufacturing materials increases risk.
The market price of common stock may be volatile.
The company is reliant on a sole supplier for certain manufacturing steps.
The company announced a reduction in force in March 2025, impacting approximately 34% of its workforce.

Future Outlook

Management believes that the Company's current cash, cash equivalents, restricted cash and investments will provide sufficient funds to enable the Company to meet its obligations for at least twelve months from the filing date of this report. The company expects to continue to incur substantial costs in order to conduct research and development activities for which additional capital will be needed, potentially through debt or equity financings.

Management Comments

Management believes that the Company's current cash, cash equivalents, restricted cash and investments will provide sufficient funds to enable the Company to meet its obligations for at least twelve months from the filing date of this report.
Management plans to continue to incur substantial costs in order to conduct research and development activities for which additional capital will be needed.
Management believes that engineered NK cells have the potential to be effective and accessible therapies for autoimmune diseases and other diseases, be well tolerated, and avoid some of the toxicities observed with other cell therapies.

Industry Context

StockSavvy.ai notes that Nkarta's focus on CAR NK cell therapies for autoimmune diseases places it in a rapidly evolving and competitive segment of the biopharmaceutical industry. The company's progress with NKX019 and its engagement with the FDA on clinical trial protocols align with industry trends towards more patient-centric and efficient trial designs.

Legal Proceedings

There are currently no claims or actions pending against the company that, in the opinion of management, are likely to have a material adverse effect on its business, results of operations, financial condition or growth prospects.

Stakeholder Impact

Shareholders may experience dilution if the company raises additional capital through equity financings.
The company's continued net losses and reliance on future funding could impact investor confidence.
Employees may be affected by the company's ongoing cost-containment measures and past workforce reductions.

Next Steps

Continue clinical development of NKX019 for autoimmune diseases.
Advance additional product candidates through preclinical and clinical development.
Seek additional capital through equity or debt financings or collaborations.
Continue to manage costs and streamline operations.

Key Dates

Date	Description
2015-07-01	Company incorporated in Delaware.
2020-06-01	Company's 2020 Performance Incentive Plan adopted.
2020-07-01	Company's initial public offering (IPO).
2021-05-05	Entered into Research Collaboration Agreement with CRISPR Therapeutics AG.
2022-04-28	Received net proceeds from secondary offering of common stock.
2023-06-01	Executed first amendment to Initial Lease Agreement for additional space.
2024-03-27	Completed underwritten public offering of common stock and pre-funded warrants.
2024-03-26	Announced reduction in force affecting 53 positions.
2024-09-01	CRISPR elected to opt-out of continuing research of initial collaboration product, NKX070.
2025-03-25	Filed Annual Report on Form 10-K for the year ended December 31, 2025.
2025-04-01	Reduction in force severance and benefit expense recognized for employees requiring future service.
2025-05-07	As of this date, 71,545,358 shares of common stock were outstanding.
2025-10-01	Entered into a lease modification agreement for vivarium space.
2025-11-01	Announced deep B-cell depletion observed in patients treated with NKX019 with Flu and Cy.
2026-01-01	Company's 2020 Plan share limit automatically increased.
2026-03-31	Quarterly period ended.
2026-04-03	Shelf Registration Statement declared effective by the SEC.
2026-04-01	Announced agreement with FDA on protocol amendments for Ntrust-1 and Ntrust-2 clinical trials.
2026-05-12	Date of report filing.

Recommendation

hold

Nkarta's Q1 2026 results show continued net losses, but also progress in clinical trial amendments for its lead candidate NKX019 and sufficient liquidity for the near term. The company's future success is heavily dependent on the clinical and regulatory outcomes of NKX019, making it a speculative investment. Given the ongoing development and potential of its platform, a 'hold' recommendation is appropriate, pending further clinical data and regulatory progress.

Keywords

Nkarta, NKX019, CAR NK cell therapy, autoimmune diseases, lupus nephritis, primary membranous nephropathy, systemic sclerosis, idiopathic inflammatory myopathy, ANCA-associated vasculitis, rheumatoid arthritis, clinical trials, FDA, biopharmaceutical, SEC filing, 10-Q

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.